浙江司太立制药股份有限公司董事会 2025年11月4日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、高级管理人员离任情况 （一）提前离任的基本情况 | 姓名 | 离任职务 | | 原定任期到期 | | 是否继续在上市 | 具体职务 | 是否存在未 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 离任时间 | 日 | 离任原因 | 公司及其控股子 | （如适用） | 履行完毕的 | | | | | | | 公司任职 | | 公开承诺 | | 姚朝阳 | 副总经理 | 2025 年 10 | 2026 年 5 月 9 | 个人原因 | 否 | 不适用 | 否 | | | | 月 31 日 | 日 | | | | | （二）根据《公司法》、《公司章程》及公司离职管理制度等相关规定，姚朝 阳先生的辞职报告自送达公司董事会之日起生效。姚朝阳先生已按公司离职管理 制度做好交接工作，其辞职不会影响公司正常的生产经营。 特此公告。 证券代码：603520 证券简称：司 ...

Company and Industry Summary Company Overview - The company is engaged in the production of pharmaceuticals, specifically focusing on domestic formulations and Active Pharmaceutical Ingredients (API) [2][4]. Key Financial Performance - For the first three quarters of 2025, the company reported revenue of 1.845 billion yuan, a year-on-year increase of 2% [4]. - The net profit attributable to shareholders was 28.82 million yuan, showing significant growth due to a low base from the previous year [4]. - The domestic formulation sales remained stable at 422 million yuan, while new products such as Jiemipule and Iodine Proamine saw sales growth exceeding three times compared to the same period last year [2][4]. API Business Performance - The API segment's shipment volume increased by 15% year-on-year to approximately 1,300 tons, with external shipments growing over 20% [2][4]. - The company expects total API shipments for the year to be between 1,800 and 2,000 tons, with several workshops having completed domestic and international GMP certifications [2][5]. Gross Margin and Cost Management - The gross margin has been continuously recovering, exceeding both the previous year's and the annual level, attributed to increased production and sales scale, as well as effective cost reduction measures [2][4]. Strategic Goals - The company aims for the formulation sales to account for about half of the entire contrast agent segment in the coming years, leveraging the iMax platform and self-operated markets [2][7]. - The goal is to fully utilize the compliant production capacity of Jiemipule by the end of next year, potentially reaching hundreds of thousands of bottles [2][5]. Market Position and Competition - The company's global market share in the API business is estimated to be around 10% to 20%, with a leading position in three main products [3][14]. - The reduction in shipment volumes from some smaller competitors presents an opportunity for the company to expand its market share [3][14]. Future Outlook - The company anticipates that the new products will contribute significantly to revenue in the fourth quarter of 2025 and into 2026, particularly following successful bids for collective procurement projects [4][5]. - The company is also focused on expanding its overseas formulation sales and has made progress in registering products in various countries [8][17]. Cost and Pricing Strategy - The overall price of raw materials has remained stable, with fluctuations of about two to three dollars this year [9]. - The company has conducted two price increases since 2022, but prices are expected to remain stable in the short term due to minimal cost fluctuations and consideration of formulation manufacturers' capacity to absorb price changes [18]. Investment and Capital Expenditure - The company has completed significant capital expenditures over the past five to six years, with all six major API varieties now industrialized and registration processes nearing completion [19]. - Future strategies include improving processes and management levels to enhance profitability while maintaining a stable dividend policy to reward investors [20].

Core Viewpoint - The company, Sital, is a significant supplier of non-ionic iodine contrast agents in China, with a comprehensive industry chain advantage and is experiencing steady revenue growth despite facing challenges in profitability and debt levels [1][2][3]. Group 1: Business Performance - For Q3 2025, Sital reported revenue of 1.845 billion yuan, ranking 10th among 47 companies in the industry, with the leading company, Puluo Pharmaceutical, generating 7.764 billion yuan [2]. - The main business composition includes contrast agents generating 1.114 billion yuan, accounting for 79.73% of total revenue, while other segments contributed 142 million yuan (10.19%) and 86.12 million yuan (6.16%) [2]. - The net profit for the same period was 29.16 million yuan, placing Sital 31st in the industry, with the top performer, Zhejiang Pharmaceutical, achieving 867 million yuan [2]. Group 2: Financial Ratios - As of Q3 2025, Sital's debt-to-asset ratio was 55.44%, higher than the previous year's 54.51% and significantly above the industry average of 27.75% [3]. - The gross profit margin was reported at 21.83%, a slight increase from 21.44% year-on-year, but still below the industry average of 35.38% [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 2.66% to 32,600, while the average number of shares held per shareholder increased by 2.73% to 13,400 [5]. - Notable changes among the top ten shareholders include the entry of new shareholders and a decrease in holdings by others, indicating a shift in shareholder composition [5]. Group 4: Management and Compensation - The chairman, Hu Jian, received a salary of 683,600 yuan in 2024, a slight increase from 683,500 yuan in 2023 [4]. - The general manager, Shen Weiyi, earned 601,100 yuan in 2024, up from 556,000 yuan in 2023, reflecting a trend of increasing compensation for top management [4]. Group 5: Market Outlook - Analysts from Huatai Securities and Ping An Securities maintain positive outlooks on Sital, citing steady revenue growth and potential improvements in gross margins due to price declines and technological upgrades [6]. - Key business highlights include the continuous production of new capacity for contrast agent raw materials and accelerated registration in overseas markets, with projected net profits for 2025-2027 expected to reach 75 million, 201 million, and 302 million yuan respectively [6].

Core Viewpoint - The company aims to enhance the financial strength and competitiveness of its subsidiary, Shanghai Sitai Pharmaceutical Co., Ltd., through a capital increase of 60 million RMB, facilitating its transition from raw materials to formulations [2] Group 1: Capital Increase - Zhejiang Sitai Pharmaceutical Co., Ltd. plans to inject 60 million RMB into Shanghai Sitai to support its operations and sustainable development [2] - Following the capital increase, the registered capital of Shanghai Sitai will rise from 50 million RMB to 56 million RMB [2] - Shanghai Sitai will remain a wholly-owned subsidiary of the company after the capital increase [2]

Core Viewpoint - The company Sital (603520.SH) reported its third-quarter results, showing modest revenue growth and significant profit increase compared to the previous year [1] Financial Performance - For the first three quarters of 2025, the company achieved total operating revenue of 1.845 billion yuan, representing a year-on-year increase of 2.24% [1] - The net profit attributable to shareholders of the parent company was 28.8248 million yuan, reflecting a substantial year-on-year growth of 221.14% [1] - The basic earnings per share were reported at 0.07 yuan [1]

Core Insights - The company reported a revenue of 1.845 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 2.24% [1] - The net profit attributable to shareholders reached 28.82 million yuan, showing a significant increase of 221.14% year-on-year [1] - The basic earnings per share (EPS) stood at 0.07 yuan [1] Financial Performance - The gross profit margin for the first three quarters of 2025 was 21.83%, an increase of 0.39 percentage points year-on-year [2] - The net profit margin was 1.58%, up 1.07 percentage points compared to the same period last year [2] - In Q3 2025, the gross profit margin improved to 27.37%, a year-on-year increase of 6.08 percentage points [2] - The net profit margin for Q3 was -0.07%, which is an increase of 2.87 percentage points year-on-year but a decrease of 2.20 percentage points quarter-on-quarter [2] Expense Management - Total operating expenses for Q3 2025 were 333 million yuan, a decrease of 24.04 million yuan year-on-year [2] - The expense ratio was 18.06%, down 1.74 percentage points from the previous year [2] - Sales expenses increased by 8.68%, while management expenses rose by 0.70%. R&D expenses decreased by 6.73%, and financial expenses saw a significant reduction of 36.27% [2] Shareholder Information - As of the end of Q3 2025, the total number of shareholders was 32,600, a decrease of 1,102 from the end of the previous half-year, representing a decline of 3.27% [2] - The average market value per shareholder increased from 127,400 yuan to 146,300 yuan, reflecting a growth of 14.88% [2] Company Overview - Zhejiang Sitaili Pharmaceutical Co., Ltd. was established on September 15, 1997, and went public on March 9, 2016 [3] - The company specializes in the production and sales of non-ionic iodine contrast agent raw materials and quinolone raw materials [3] - The revenue composition includes 79.73% from contrast agents, 10.19% from other supplementary products, 6.16% from other sources, 2.41% from CMO/CDMO, and 1.52% from quinolone series [3] - The company is classified under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and raw materials [3]

浙江司太立制药股份有限公司 董事会薪酬与考核委员会议事规则 浙江司太立制药股份有限公司 第 1 页 董事会薪酬与考核委员会议事规则 第一章 总 则 第一条 为进一步建立健全浙江司太立制药股份有限公司（以下简称"公司"）董 事及高级管理人员的考核和薪酬管理制度，完善公司治理结构，根据《中华人民共和国 公司法》、《上市公司治理准则》、《上市公司独立董事管理办法》及《浙江司太立制药股 份有限公司章程》（以下简称"《公司章程》"）、《董事会议事规则》等有关规定，公司设 立董事会薪酬与考核委员会（以下简称"薪酬与考核委员会"），并制定本议事规则。 第二条 薪酬与考核委员会是董事会下设的专门委员会，负责制定董事、高级管 理人员的考核标准并进行考核，制定、审查董事、高级管理人员的薪酬政策与方案。 第三条 本议事规则所称董事是指在本公司领取薪酬的董事；高级管理人员是指 董事会聘任的总经理、副总经理、董事会秘书、财务负责人以及《公司章程》规定的其 他高级管理人员。 第二章 人员组成 第四条 薪酬与考核委员会成员由三名董事组成，其中独立董事应当过半数。 第五条 薪酬与考核委员会委员由董事长、二分之一以上独立董事或者全体董事 三分 ...

浙江司太立制药股份有限公司 内部控制制度 浙江司太立制药股份有限公司 内部控制制度 第一章 总则 1 第一条 为加强浙江司太立制药股份有限公司（以下简称"公司"）内部控 制，促进公司规范运作和健康发展，防范和化解公司日常经营运作中可能出现的 各类风险，保护投资者合法权益，根据《中华人民共和国公司法》《中华人民共和 国证券法》《上海证券交易所股票上市规则》（以下简称"《股票上市规则》"）《上 海证券交易所上市公司自律监管指引第 1 号——规范运作》《企业内部控制基本规 范》等规定以及《浙江司太立制药股份有限公司章程》（以下简称"《公司章程》"）， 结合公司的实际情况，制定本制度。 第二条 本制度所称内部控制，是由公司董事会、管理层和全体员工实施的， 旨在实现控制目标的过程。内部控制的目标是合理保证企业经营管理合法合规、 资产安全、财务报告及相关信息真实完整，提高经营效率和效果，促进企业实现 发展战略。公司的内部控制包括内部环境、风险评估、控制活动、信息与沟通、 内部监督等要素。 第三条 公司建立与实施内部控制，遵循下列原则： （一） 全面性原则。内部控制应当贯穿决策、执行和监督全过程，覆盖公 司及其属单位的各种 ...

浙江司太立制药股份有限公司 募集资金管理办法 浙江司太立制药股份有限公司 募集资金管理办法 第一章 总则 第一条 为进一步规范浙江司太立制药股份有限公司（以下简称"公司"） 募集资金的管理和使用，提高募集资金使用的效率和效果，防范资金使用风险， 确保资金使用安全，切实保护投资者利益，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《首次公开发行股票注册管理办法》《上市公司证券发行注册管理办法》《上市 公司募集资金监管规则》《上海证券交易所股票上市规则》（以下简称"《股票 上市规则》"）、《上海证券交易所上市公司自律监管指引第1号——规范运作》 等有关法律、行政法规和规范性文件的规定，结合公司实际情况，制定本办法。 第二条 本办法所称募集资金，是指公司通过发行股票或者其他具有股权性 质的证券，向投资者募集并用于特定用途的资金，但不包括公司为实施股权激励 计划募集的资金。 本办法所称超募资金是指实际募集资金净额超过计划募集资金金额的部分。 第三条 公司董事会应当持续关注募集资金存放、管理和使用情况，有效防 范投资风险，提高募集资金使用效益。 第四条 ...

董事会审计委员会议事规则 第一章 总 则 第一条 为强化浙江司太立制药股份有限公司（以下简称"公司"）董事会决策功 能，确保董事会对经理层的有效监督，完善公司治理结构，根据《中华人民共和国公司 法》、《上市公司治理准则》、《上市公司独立董事管理办法》及《浙江司太立制药股份有 限公司章程》（以下简称"《公司章程》"）、《董事会议事规则》等有关规定，公司设立 董事会审计委员会（以下简称"审计委员会"），并制定本议事规则。 第二条 审计委员会是董事会下设的专门委员会，行使《公司法》规定的监事会 的职权，负责审核公司财务信息及其披露、监督及评估内外部审计工作和内部控制。 浙江司太立制药股份有限公司 董事会审计委员会议事规则 浙江司太立制药股份有限公司 主任委员由审计委员会选举推荐，并报请董事会批准，由董事会任命。 主任委员不能或无法履行职责时，由其指定一名其他委员代行其职权；主任委员既 不履行职责，也不指定其他委员代行其职责时，任何一名委员均可将有关情况向公司董 事会报告，由公司董事会指定一名委员履行召集人职责。 第六条 审计委员会任期与董事会任期一致，委员会任期届满，可连选连任。审 计委员会委员任期届满前，公司可以 ...